Buserelin Peptide: Suprefact, GnRH Agonist Uses and Safety Limits

Buserelin is a peptide drug with a very different evidence profile from research-market hormone peptides. It is a synthetic nonapeptide analog of gonadotropin-releasing hormone, often called a GnRH agonist or LHRH analogue, sold mainly under the brand name Suprefact, with Suprecur and Profact used in some markets.

The key is regulatory and product-specific context. Buserelin is a prescription medicine in the countries where it is approved, such as Canada and parts of Europe, and it is notably not approved for medical use in the United States. Its labeled and protocol uses, routes, doses and safety monitoring differ by indication, and none of them should be reduced to a generic "hormone peptide" protocol.

For related endocrine context, compare this guide with leuprolide, gonadorelin, kisspeptin, oxytocin, what peptides are, and the peptide half-life guide. Because buserelin can be injected, general handling concepts in how to inject peptides safely still do not replace the product label or a clinician's instructions.

This guide is educational and not medical advice. Buserelin is a prescription medicine where it is approved at all. It should be started, monitored, changed or stopped only through qualified medical care.

Buserelin At A Glance

How A GnRH Agonist Like Buserelin Lowers Hormones

Native GnRH is released in pulses from the hypothalamus. Those pulses tell the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn regulate testosterone, estradiol, ovulation and related reproductive-hormone pathways.

Buserelin is a superagonist at the GnRH receptor. Reported pharmacology places its potency for inducing LH and FSH release at many times that of native GnRH. That sounds like it should drive the pathway, and at first it does: early in therapy, gonadotropins and sex steroids can rise. In prostate cancer this early surge is described as tumor flare.

With continuous, non-pulsatile exposure, the pituitary GnRH receptors become desensitized and downregulated. LH and FSH fall, and sex-steroid production falls into a reversible, medically castrate range. That delayed suppression is the therapeutic goal in prostate cancer and endometriosis. In IVF protocols the same suppression is used to silence the patient's own cycle so that stimulation can be controlled.

Buserelin has poor oral bioavailability and a short elimination half-life reported at roughly 72 to 80 minutes regardless of route, which is why it is given as repeated subcutaneous injections or as an intranasal spray rather than as a pill. Roughly half of an absorbed dose is reported to be excreted unchanged in urine, with peptidase metabolism in the liver, kidney and gut. The short half-life is a useful contrast to depot products; see the peptide half-life guide for why that matters for dosing frequency.

Approval Status And Labeled Uses

Buserelin was first described in 1976 and introduced for medical use in 1984, developed by Hoechst AG of Frankfurt, Germany (the rights now sit with Sanofi). Intranasal buserelin is often cited as the first GnRH agonist shown to achieve medical castration in humans.

Because approval varies by country, a "buserelin" search can feel contradictory. The honest framing is that it is a genuine, approved GnRH agonist in some markets, an unapproved drug in others, and never a casual wellness compound.

What The Evidence Supports

In advanced prostate cancer, buserelin is used for androgen deprivation. The objective is testosterone suppression to a castrate range, and product labeling focuses on achieving and maintaining that suppression across the dosing interval. The labels are also explicit that serum testosterone rises in the first days of treatment, which can transiently worsen disease, so the early flare is a core feature rather than a footnote.

In endometriosis, the logic is estrogen suppression. Lowering estradiol can reduce endometriosis-associated pain, but it also produces hypoestrogenic side effects, which is why treatment duration is capped and bone health is watched.

In IVF and assisted reproduction, buserelin has a substantial trial record used as pituitary down-regulation before gonadotropin stimulation. The evidence here is nuanced and honest about limits. Randomized and comparative studies have examined whether buserelin down-regulation improves pregnancy and implantation outcomes, and several found no clear advantage from short-course buserelin when follicular-phase management was otherwise adequate. Other work compared a GnRH agonist trigger such as buserelin against hCG for final oocyte maturation in antagonist cycles. The takeaway is that buserelin is a useful, well-studied tool in structured fertility protocols, not a guaranteed fertility booster.

Across all of these, the evidence base is condition-specific clinical trials and official labels, not open-label wellness use. That is the opposite of how research-market peptides are usually promoted.

Safety Limits

Buserelin's safety profile follows directly from its mechanism and from the product labels. It first stimulates and then suppresses hormone signaling, and both phases matter.

Pharmacovigilance work comparing GnRH analogs has examined how adverse-event patterns differ across the class, reinforcing that these drugs are not interchangeable and that monitoring is indication-specific.

How To Evaluate A Buserelin Claim

Ask six questions.

First, is it approved where you are? Buserelin has no FDA approval in the United States, so any US "buserelin protocol" sold outside a clinical setting is a red flag.

Second, which product and route? Suprefact injection and Suprefact nasal solution are different presentations with different dosing.

Third, which indication? Prostate cancer, endometriosis and IVF down-regulation are distinct goals with distinct schedules.

Fourth, does the source mention early flare? Any description of GnRH agonist therapy that omits the initial stimulation phase is incomplete.

Fifth, does it address bone, metabolic, cardiovascular or pregnancy risk where relevant?

Sixth, is it using prescription-label or trial evidence to imply unregulated human use? GnRH agonists are not "hormone optimization" peptides, and stacking buserelin into a wellness routine based on "hormone balance" language ignores what the drug actually does. Compare its narrow, supervised role to the way upstream signaling peptides like kisspeptin are studied if you want a sense of how different these reproductive-axis tools really are.

Bottom Line

Buserelin is a real peptide medicine, an early and potent GnRH agonist with label-backed evidence in specific hormone-suppression settings. It can suppress testosterone or estradiol pathways after an initial stimulation phase, which makes it useful in advanced prostate cancer, endometriosis and IVF down-regulation where it is approved or protocol-supported.

The same mechanism sets the limits. Buserelin is not FDA-approved in the United States, not a casual hormone peptide, and not a general wellness protocol. Country of approval, product and route, indication, early-flare management, bone and metabolic monitoring, and pregnancy precautions are all central to its safe use, and all of that belongs with a clinician rather than a vendor.

References

1. Health Canada. Suprefact (buserelin acetate) Product Monograph.

2. Health Canada. Suprefact (buserelin acetate) Product Monograph, archived version.

3. BC Cancer. Buserelin Drug Monograph.

4. Cancer Care Ontario. Buserelin Drug Formulary Monograph.

5. Beckers NGM, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.

6. The use of the GnRH analogue buserelin for IVF -- does it improve fertility?.

7. Short-term utilization of a gonadotropin-releasing hormone agonist (buserelin) for induction of ovulation in an in vitro fertilization program.

8. Exposure to LHRH agonists in early pregnancy following the commencement of mid-luteal buserelin for IVF stimulation.

9. PLOS One. Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: a real-world pharmacovigilance study.